Abstract:Abstract Pharmacologic concentrations of ascorbate have been shown to act as a pro-oxidant anti-cancer agent. Our previous work has showed that pharmacologic ascorbate worked synergistically with gemcitabine in 8 pancreatic cancer cells lines, and in gemcitabine responsive and non-responsive mouse tumor models. This study aimed to investigate the mechanisms for this synergistic effect. In PANC-1 pancreatic cancer cells treated with 2.5 mM ascorbate, real time RT-PCR showed increased mRNA expression levels of E-cadherin, and decreased levels of Vimentin, indicating a reversal/inhibition of epithelial-mesenchymal transition (EMT). The inhibition of EMT was attribute to up-regulation of microRNAs mir429 and mir 200 family, which binds to to 3′ URTs of Zeb-1 and Zeb-2 mRNAs, thus inhibited Zeb-1/2 mRNA translation and accelerated their deadenylation and subsequent exonucleolytic digestion. Consistant with the mir429 and 200 increase, real-time RT-PCR showed decreased in Zeb-1. Since Zeb-1 is a repressor of E-cadherin, the inhibition in Zeb-1 resulted in the increased level of E-cadherin. Moreover, mRNAs for multiple MMPs were also found inhibited by ascorbate treatment, while collagen type IV and type II were largely increased. Relatively, mir21 was found decreased by ascorbate treatment. Mir21 is an oncomir that promotes cancer invasion. It inhibits TIMP-3 and up-regulate MMPs, and thus its inhibition is associated with repression of MMPs. At cellular level, immulofluorescence clearly showed an increase in E-cadherin and decrease in Vimentin expression, which confirmed the RT-PCR results in indicating EMT inhibition. As EMT is highly related to drug resistance, we co-treated PANC-1 cell with ascorbate and gemcitabine. PANC-1 cells exhibited a highly “EMTed” phenotype and were resistant to gemcitabine single-drug treatment. The combination treatment of ascorbate and gemcitabine dramatically increased cell death compared to gemcitabine alone. Using Chou-Talalay's constant ratio design, gemcitabine IC50 was decreased 3.5-fold, and gemcitabine IC90 was decreased 11.5-fold. In PANC-1 orthotopic mouse tumor model (n=3 for each group), live animal imaging showed predominant tumor growth and metastasis in saline-treated controls, but tumor regression in ascorbate (4 g/kg/day, i.p.) treated mice. At day 54, 2 of the 3 ascorbate-treated mice were tumor-free. Experiments are underway with larger groups of mice and with ascorbate/gemcitabine combination treatment to examine tumor growth and metastasis. Collectively, these data demonstrated that ascorbate at pharmacological doses inhibited pancreatic cancer growth. Inhibition in EMT by ascorbate resulted in a strong synergistic effect between ascorbate and gemcitabine. These results suggest a rational combination of high dose parenteral ascorbate and gemcitabine in treating pancreatic cancer, one of the most lethal cancers worldwide. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2409. doi:1538-7445.AM2012-2409

Juglone-ascorbate treatment enhances reactive oxygen species mediated mitochondrial apoptosis in pancreatic cancer

Juglone Effects by Dual Way on mTOR Gene Expression, Which Plays Central Role in Cell Growth, Survival and Metabolism, in PANC-1 and BxPC-3 Pancreatic Cancer Cell Lines

The effects of Juglone-Selenium combination on invasion and metastasis in pancreatic cancer cell lines

The Anti-Glioma Effect of Juglone Derivatives through ROS Generation

Juglone Potentiates TRAIL-induced Apoptosis in Human Melanoma Cells Via Activating the ROS-p38-p53 Pathway

Juglone Potentiates BRAF Inhibitor‑induced Apoptosis in Melanoma Through Reactive Oxygen Species and the P38‑p53 Pathway

Juglone Induces Apoptosis of Tumor Stem-Like Cells Through ROS-p38 Pathway in Glioblastoma.

Juglanthraquinone C Induces Intracellular ROS Increase and Apoptosis by Activating the Akt/Foxo Signal Pathway in HCC Cells

Cytotoxicity of juglone and thymoquinone against pancreatic cancer cells

Synergy Between Arsenic Trioxide and JQ1 on Autophagy in Pancreatic Cancer

Palladium concave nanocrystals with high-index facets accelerate ascorbate oxidation in cancer treatment

Selective Induction of Cellular Toxicity and Anti-tumor Efficacy by N-Methylpiperazinyl Diarylidenylpiperidone and its Pro-nitroxide Conjugate through ROS-mediated Mitochondrial Dysfunction and G2/M Cell-cycle Arrest in Human Pancreatic Cancer

Anti-proliferative Effect of Juglone from Juglans Mandshurica Maxim on Human Leukemia Cell HL-60 by Inducing Apoptosis Through the Mitochondria-Dependent Pathway

Juglone Inhibits Tumor Metastasis by Regulating Stemness Characteristics and the Epithelial-to-Mesenchymal Transition in Cancer Cells both in Vitro and in Vivo

Nardoguaianone L Isolated from Nardostachys jatamansi Improved the Effect of Gemcitabine Chemotherapy via Regulating AGE Signaling Pathway in SW1990 Cells

Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer

Aqueous extracts of Paeonia suffruticosa modulates mitochondrial proteostasis by reactive oxygen species-induced endoplasmic reticulum stress in pancreatic cancer cells

Impact of Juglone, a PIN1 İnhibitor, on Oral Carcinogenesis Induced by 4-Nitroquinoline-1-Oxide (4NQO) in Rat Model

Arsenic Sulfide Amplifies JQ1 Toxicity Via Mitochondrial Pathway in Gastric and Colon Cancer Cells

Abstract 2409: Pharmacologic Ascorbate Inhibits Pancreatic Cancer Cell EMT and Sensitizes Cancer Cells to Gemcitabine

The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo.